Terrie Curran Sells 16,851 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 16,851 shares of the firm’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the completion of the transaction, the insider now owns 410,784 shares of the company’s stock, valued at $3,742,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Phathom Pharmaceuticals Price Performance

Shares of Phathom Pharmaceuticals stock opened at $11.05 on Thursday. Phathom Pharmaceuticals, Inc. has a 1 year low of $6.07 and a 1 year high of $17.02. The company has a current ratio of 10.25, a quick ratio of 10.22 and a debt-to-equity ratio of 5.56. The company has a 50 day simple moving average of $8.43 and a two-hundred day simple moving average of $8.83.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.12. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same quarter in the previous year, the firm earned ($1.33) earnings per share. As a group, research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. lifted its holdings in shares of Phathom Pharmaceuticals by 2,715.2% in the 2nd quarter. Osaic Holdings Inc. now owns 4,251 shares of the company’s stock worth $59,000 after acquiring an additional 4,100 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of Phathom Pharmaceuticals by 112.6% in the second quarter. Quantbot Technologies LP now owns 5,527 shares of the company’s stock worth $46,000 after buying an additional 2,927 shares during the period. Legal & General Group Plc increased its stake in shares of Phathom Pharmaceuticals by 20.1% in the second quarter. Legal & General Group Plc now owns 6,328 shares of the company’s stock worth $54,000 after buying an additional 1,061 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Phathom Pharmaceuticals by 355.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,626 shares of the company’s stock worth $60,000 after buying an additional 5,171 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Phathom Pharmaceuticals by 371.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company’s stock worth $87,000 after buying an additional 6,641 shares during the period. 99.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, March 22nd.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.